About Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Pharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:TTPH
- CUSIP: N/A
- Web: www.tphase.com
- Market Cap: $318.57 million
- Outstanding Shares: 51,053,000
- 50 Day Moving Avg: $6.89
- 200 Day Moving Avg: $7.14
- 52 Week Range: $3.11 - $9.93
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -3.04
- P/E Growth: -0.01
- Annual Revenue: $5.01 million
- Price / Sales: 63.59
- Book Value: $2.67 per share
- Price / Book: 2.34
- EBITDA: ($104,990,000.00)
- Net Margins: -2,092.20%
- Return on Equity: -79.79%
- Return on Assets: -71.63%
- Current Ratio: 6.12%
- Quick Ratio: 6.12%
- Average Volume: 1.30 million shs.
- Beta: 2.57
- Short Ratio: 0.89
Frequently Asked Questions for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
What is Tetraphase Pharmaceuticals' stock symbol?
Tetraphase Pharmaceuticals trades on the NASDAQ under the ticker symbol "TTPH."
How were Tetraphase Pharmaceuticals' earnings last quarter?
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) issued its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.76) by $0.07. The company had revenue of $1.59 million for the quarter, compared to the consensus estimate of $1.54 million. Tetraphase Pharmaceuticals had a negative return on equity of 79.79% and a negative net margin of 2,092.20%. The company's revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.47) earnings per share. View Tetraphase Pharmaceuticals' Earnings History.
When will Tetraphase Pharmaceuticals make its next earnings announcement?
Where is Tetraphase Pharmaceuticals' stock going? Where will Tetraphase Pharmaceuticals' stock price be in 2017?
6 brokers have issued twelve-month price targets for Tetraphase Pharmaceuticals' shares. Their forecasts range from $4.00 to $24.00. On average, they expect Tetraphase Pharmaceuticals' share price to reach $14.00 in the next twelve months. View Analyst Ratings for Tetraphase Pharmaceuticals.
Are investors shorting Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totalling 2,645,906 shares, a decrease of 32.0% from the August 31st total of 3,889,264 shares. Based on an average trading volume of 920,846 shares, the short-interest ratio is currently 2.9 days. Currently, 5.2% of the shares of the company are short sold.
Who are some of Tetraphase Pharmaceuticals' key competitors?
Some companies that are related to Tetraphase Pharmaceuticals include SciClone Pharmaceuticals (SCLN), AMAG Pharmaceuticals (AMAG), Corium International (CORI), Collegium Pharmaceutical (COLL), Teligent (TLGT), Aceto Corporation (ACET), Aquinox Pharmaceuticals (AQXP), Neos Therapeutics (NEOS), Allergy Therapeutics plc (AGY), Adamis Pharmaceuticals Corporation (ADMP), BioDelivery Sciences International (BDSI), Marinus Pharmaceuticals (MRNS), Aralez Pharmaceuticals (ARLZ), BioLife Solutions (BLFS), Diurnal Group PLC (DNL), Histogenics Corporation (HSGX), Juniper Pharmaceuticals (JNP) and Evoke Pharma (EVOK).
Who are Tetraphase Pharmaceuticals' key executives?
Tetraphase Pharmaceuticals' management team includes the folowing people:
- Leonard Patrick Gage Ph.D., Chairman of the Board of Directors
- Guy Macdonald, President and Chief Executive Officer, Director
- Christopher Watt, Principal Financial Officer, Principal Accounting Officer, Senior Vice President - Finance
- Maria D. Stahl, Senior Vice President, General Counsel
- Patrick T. Horn M.D. Ph.D., Chief Medical Officer
- Jeffrey A. Chodakewitz M.D., Director
- Geraldine A. Henwood Ph.D., Director
- Garen G. Bohlin, Independent Director
- John G. Freund M.D., Independent Director
- Nancy J. Wysenski, Independent Director
How do I buy Tetraphase Pharmaceuticals stock?
Shares of Tetraphase Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetraphase Pharmaceuticals' stock price today?
MarketBeat Community Rating for Tetraphase Pharmaceuticals (NASDAQ TTPH)MarketBeat's community ratings are surveys of what our community members think about Tetraphase Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Tetraphase Pharmaceuticals stock can currently be purchased for approximately $6.24.
Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Hold Ratings, 4 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$14.00 (124.36% upside)|Consensus Price Target History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/4/2017||BMO Capital Markets||Boost Price Target||Outperform||$13.00 -> $24.00||N/A|
|9/17/2017||Needham & Company LLC||Reiterated Rating||Hold||High|
|9/12/2017||Stifel Nicolaus||Reiterated Rating||Buy||$13.00||Low|
|8/28/2017||Piper Jaffray Companies||Initiated Coverage||Overweight -> Overweight||$14.00||High|
|7/11/2017||HC Wainwright||Initiated Coverage||Buy -> Buy||$15.00||High|
|11/19/2015||SunTrust Banks, Inc.||Upgrade||Neutral -> Buy||$12.00 -> $21.00||N/A|
Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)Earnings History by Quarter for Tetraphase Pharmaceuticals (NASDAQ TTPH)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/2/2017||Q2 2017||($0.76)||($0.83)||$1.54 million||$1.59 million||View||N/A|
|5/2/2017||Q1 2017||($0.60)||($0.79)||$1.46 million||$1.48 million||View||N/A|
|3/8/2017||Q4||($0.60)||($0.61)||$1.28 million||$1.09 million||View||Listen|
|11/3/2016||($0.50)||($0.58)||$1.58 million||$0.90 million||View||N/A|
|8/4/2016||Q2||($0.46)||($0.47)||$2.05 million||$1.20 million||View||N/A|
|5/4/2016||Q1||($0.44)||($0.46)||$2.20 million||$2.00 million||View||N/A|
|2/23/2016||Q4||($0.44)||($0.50)||$3.23 million||$2.47 million||View||Listen|
|11/2/2015||Q315||($0.65)||($0.49)||$3.20 million||$2.90 million||View||N/A|
|8/5/2015||Q215||($0.62)||($0.72)||$2.73 million||$3.30 million||View||N/A|
|5/6/2015||Q115||($0.64)||($0.66)||$2.90 million||$3.00 million||View||N/A|
|3/5/2015||($0.54)||($0.69)||$2.74 million||$3.07 million||View||N/A|
|11/10/2014||Q314||($0.56)||($0.55)||$2.86 million||$2.29 million||View||N/A|
|8/12/2014||Q214||($0.54)||($0.71)||$2.79 million||$1.30 million||View||N/A|
|5/12/2014||Q114||($0.45)||($0.53)||$2.97 million||$2.50 million||View||N/A|
|11/11/2013||Q3||($0.39)||($0.49)||$2.43 million||$2.20 million||View||N/A|
|5/13/2013||Q113||($0.27)||($0.30)||$2.49 million||$2.70 million||View||N/A|
Earnings Estimates for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
2017 EPS Consensus Estimate: ($2.44)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Insider Ownership Percentage: 5.50%Insider Trades by Quarter for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Institutional Ownership Percentage: 41.73%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|8/22/2017||Jacques Dumas||Insider||Sell||17,500||$6.00||$105,000.00|| |
|8/17/2017||Jacques Dumas||Insider||Sell||7,155||$5.86||$41,928.30|| |
|3/15/2017||L Patrick Gage||Director||Buy||11,000||$7.49||$82,390.00|| |
|9/1/2015||Guy Macdonald||insider||Sell||10,000||$41.57||$415,700.00|| |
|8/14/2015||David Charles Lubner||CFO||Sell||9,500||$42.92||$407,740.00|| |
|8/13/2015||Patrick Taylor Horn||Insider||Sell||10,000||$44.69||$446,900.00|| |
|8/12/2015||L Patrick Gage||Director||Sell||15,000||$45.00||$675,000.00|| |
|7/20/2015||Guy Macdonald||Insider||Sell||15,000||$50.72||$760,800.00|| |
|7/14/2015||David Charles Lubner||CFO||Sell||7,500||$48.92||$366,900.00|| |
|7/13/2015||Patrick Taylor Horn||Insider||Sell||10,000||$48.93||$489,300.00|| |
|7/6/2015||John Craig Thompson||COO||Sell||10,000||$47.91||$479,100.00|| |
|7/1/2015||Guy Macdonald||Insider||Sell||10,000||$47.92||$479,200.00|| |
|6/15/2015||David Charles Lubner||CFO||Sell||17,500||$41.45||$725,375.00|| |
|6/15/2015||John Craig Thompson||COO||Sell||10,000||$41.51||$415,100.00|| |
|6/8/2015||John Craig Thompson||COO||Sell||22,499||$43.26||$973,306.74|| |
|6/1/2015||Guy Macdonald||Insider||Sell||16,087||$41.89||$673,884.43|| |
|5/11/2015||Guy Macdonald||Insider||Sell||20,000||$41.51||$830,200.00|| |
|1/20/2015||Guy Macdonald||Insider||Sell||34,135||$36.59||$1,248,999.65|| |
|10/2/2014||John Gordon Freund||Director||Sell||247,734||$20.88||$5,172,685.92|| |
|10/1/2014||John Gordon Freund||Director||Sell||142,146||$20.84||$2,962,322.64|| |
|9/30/2014||John Gordon Freund||Director||Sell||152,266||$20.18||$3,072,727.88|| |
|9/29/2014||John Gordon Freund||Director||Sell||95,648||$20.19||$1,931,133.12|| |
|9/23/2014||Guy Macdonald||Insider||Sell||10,000||$18.47||$184,700.00|| |
|9/17/2014||Guy Macdonald||Insider||Sell||10,000||$18.00||$180,000.00|| |
|9/17/2014||John Gordon Freund||Director||Sell||144,356||$17.21||$2,484,366.76|| |
|9/12/2014||John Gordon Freund||Director||Sell||55,644||$17.01||$946,504.44|| |
|9/8/2014||John Gordon Freund||Director||Sell||16,700||$15.01||$250,667.00|| |
|9/4/2014||John Gordon Freund||Director||Sell||183,300||$15.05||$2,758,665.00|| |
|9/3/2014||John Gordon Freund||Director||Sell||142,100||$15.04||$2,137,184.00|| |
|8/20/2014||Guy Macdonald||Insider||Sell||10,000||$11.59||$115,900.00|| |
|7/18/2014||Guy Macdonald||Insider||Sell||15,000||$10.61||$159,150.00|| |
|6/23/2014||John Gordon Freund||Director||Sell||47,184||$13.77||$649,723.68|| |
|6/20/2014||John Gordon Freund||Director||Sell||152,816||$13.39||$2,046,206.24|| |
|6/17/2014||David Charles Lubner||CFO||Sell||13,530||$12.51||$169,260.30|| |
|6/17/2014||Guy Macdonald||Insider||Sell||15,000||$12.28||$184,200.00|| |
|5/19/2014||Guy Macdonald||Insider||Sell||15,000||$9.00||$135,000.00|| |
|5/19/2014||Steven Ph.D. Gullans||Director||Buy||25,000||$9.24||$231,000.00|| |
|5/14/2014||L Patrick Gage||Director||Buy||5,000||$9.25||$46,250.00|| |
|4/14/2014||Guy Macdonald||Insider||Sell||15,000||$9.69||$145,350.00|| |
|3/20/2014||Joyce Sutcliffe||SVP||Sell||11,494||$12.41||$142,640.54|| |
|3/6/2014||David Charles Lubner||CFO||Sell||4,510||$13.65||$61,561.50|| |
|2/20/2014||Joyce Sutcliffe||SVP||Sell||11,494||$14.00||$160,916.00|| |
|2/12/2014||David Charles Lubner||CFO||Sell||4,506||$13.92||$62,723.52|| |
|2/7/2014||David Charles Lubner||CFO||Sell||9,928||$14.22||$141,176.16|| |
|2/5/2014||Joyce Sutcliffe||SVP||Sell||11,494||$13.93||$160,111.42|| |
|9/18/2013||Ventures Vi Lp Cmea||major shareholder||Sell||100,000||$10.20||$1,020,000.00|| |
|9/17/2013||Ventures Vi Lp Cmea||major shareholder||Sell||53,468||$9.26||$495,113.68|| |
|3/25/2013||John Gordon Freund||Director||Buy||681,012||$7.00||$4,767,084.00|| |
|3/25/2013||Medical Fund Lp Excel||Major Shareholder||Buy||496,121||$7.00||$3,472,847.00|| |
|3/20/2013||Fmr Llc||Insider||Buy||642,857||$7.00||$4,499,999.00|| |
Headline Trends for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Latest Headlines for Tetraphase Pharmaceuticals (NASDAQ:TTPH)
Loading headlines, please wait.
Tetraphase Pharmaceuticals (TTPH) Chart for Tuesday, October, 24, 2017